Finanzas de First Tracks Biotherapeutics Inc (TRAX)TRAXFirst Tracks Biotherapeutics Inc

In the context of the broader market, TRAX competes directly with industry leaders such as KARD and TYRA. With a market capitalization of $1.55B, it holds a leading position in the sector. When comparing efficiency, TRAX's gross margin of N/A stands against KARD's N/A and TYRA's N/A. Such benchmarking helps identify whether First Tracks Biotherapeutics Inc is trading at a premium or discount relative to its financial performance.

TRAX has a current ratio of 14.28, indicating strong liquidity, but it has reported negative net income in recent quarters, with the latest being -33,374,000 USD in Q2 2026. The forward P/E ratio is 0, suggesting that the company is not yet profitable, but this is typical for biotech firms in development stages.